## Day 1 – Monday, November 11, 2019

07:00-08:30	Registration
08:30-08:45	Ingmar Hoerr: Welcome
08:45-09:45	<b>Keynote Speaker: Matthias Hentze:</b> Hidden treasures of the RNA world: RBPs from moonlighting to riboregulation
09:45-12:20	mRNA Biology & Regulation / Chair: Jacek Jemielity
09:45-10:05	Niek Sanders: Small-molecule-responsive mRNAs
10:05-10:25	Jacob Becraft: A synthetic biology platform for next generation "smart" mRNAs
10:25-10:45	Joanna Kowalska: Alternate endings: towards understanding of unconventional RNA caps
10:45-11:00	Coffee Break
11:00-11:20	<b>Hadi Valadi:</b> Linkage between LNP-mRNA Escape and Packaging into Evs - mRNA loading into Evs and in vivo delivery
11:20-11:40	<b>Chantal Pichon:</b> Engineered yeast mutants for accumulation and package mRNA of interest: a proof of concept study
11:40-12:00	Piotr Kowalski: Engineering mRNA nanotherapeutics for selective delivery and sustained translation
12:00-12:20	<b>Juozas Šiurkus:</b> Latest State-of-Art Disposable Bioprocesses for Production of High Quality Recombinant Enzymes for mRNA and DNA Workflows
12:20-12:50	Short Presentations / Chair: Michael D. Buschmann
12:20-12:30	<b>Anton McCaffrey:</b> mRNA Expressing Cytosine and Adenine Base Editors Mediate Efficient Base Corrections In Vitro and In Vivo
12:30-12:40	Monica Wu: Understanding the nature and source of dsRNA by-products during in vitro transcription.
12:40-12:50	Aleks Schein: Extra-long mRNA for treatment of Duchenne Muscular Dystrophy
12:50-13:50	Lunch & Poster Session
13:50-16:50	Delivery / Chair: Colin Pouton
13:50-14:10	Dan Peer: A Modular Platform for RNA Therapeutics
14:10-14:30	Hidetaka Akita: An Intracellular responsive lipid like material (ssPalm) as a RNA delivery platform
14:30-14:50	Phil Santangelo: Mucosal delivery of mRNA and applications to disease prevention
14:50-15:10	<b>Rein Verbeke:</b> Lipid nanoparticles co-loaded with mRNA and glycolipid adjuvants (GALSOMES) induce pluripotent antitumor immunity through conventional T cells and natural killer T cells
15:10-15:30	Hana Totary-Jain: Effective delivery of mRNA using self-assembled peptide-based nanoparticles
15:30-15:50	Thomas D. Madden: Characterizing the therapeutic application of messenger RNA-lipid nanoparticles
15:50-16:10	Coffee Break
16:10-16:30	<b>Andreas Wagner:</b> Guiding RNA formulations from laboratory into clinical trials. Lessons learned from development and optimization of liposomal/LNP formulations.
16:30-16:50	<b>Norbert Maurer:</b> Recent Advances in Lipid Nanoparticle-Mediated Drug Delivery – A CDMO perspective
16:50-18:10	Therapeutic Area: mRNA Therapeutics / Chair: Friedrich Metzger
16:50-17:10	<b>Stefan Hauser:</b> Messenger RNA as novel treatment strategy for Hereditary Spastic Paraplegia Type 5 (SPG5)
17:10-17:30	<b>Joseph Rosenecker:</b> Self-assembled peptide-poloxamine nanoparticles enable in vivo genome restoration of the CFTR- gene in murine airways: using mRNA for transient expression of transposase
17:30-17:50	James Wilson: mRNA for Treating Liver Metabolic Disease
17:50-18:10	<b>Janos Szebeni:</b> Infusion reactions as a safety barrier in RNA therapy: animal models for prediction and prevention
until 20:00	Poster Session & Exhibition
20.00	Networking Recention

## Day 2 – Tuesday, November 12, 2019

08:30-09:50	Therapeutic Area: Prophylactic Vaccines / Chair: Norbert Pardi
08:30-08:50	<b>Karin Loré:</b> Understanding Innate Immune Activation by mRNA Vaccines for Induction of Strong B Cell Responses
08:50-09:10	Lori Panther: Phase 1 Trial of a mRNA Vaccine Against Cytomegalovirus (CMV) Infection
09:10-09:30	Drew Weissman: Nucleoside-modified mRNA-lipid nanoparticle vaccine platform
09:30-09:50	<b>Anna K. Blakney:</b> Big is beautiful: Enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer
09:50-10:10	Coffee Break
10:10-11:30	Therapeutic Area: Oncology / Chair: Kristiaan Thielemans
10:10-10:30	Özlem Türeci: mRNA-based targeted immunotherapy
10:30-10:50	<b>Zwi Berneman:</b> Therapeutic vaccination of cancer patients with dendritic cells electroporated with Wilms' tumor 1 (WT1) mRNA: Clinical responses, increased survival and correlation with WT1-specific T-cell response induced by the transfected dendritic cells
10:50-11:10	<b>Ulrike Gnad-Vogt:</b> Next generation mRNA cancer vaccines and RNA- based intratumoral immunomodulation
11:10-11:30	Matthias Stephan: Developing T-cell therapies for the masses
11:30-12:10	Presentations of small companies / Chair: Katalin Karikó
11:30-11:35	Anitha Thomas: Precision NanoSystems, Canada
11:35-11:40	Carmen Plasencia: AROMICS, Spain
11:40-11:45	Daniel Tondera: Pantherna Therapeutics, Germany
11:45-11:50	John Ramunas: Rejuvenation Technologies, USA
11:50-11:55	Guido Krupp: AmpTec, Germany
11:55-12:00	Ingo Nagler: BIA, Slovenia
12:00-12:05	Shiro Akinaga: AccuRna, Japan
12:05-12:10	Stefano Croce: Baseclick, Germany
12:10-13:10	Lunch & Poster Session
13:10-14:10	Regulatory Session
14:10-15:30	Short Talks / Chair: Roland Brock
14:10-14:20	<b>Harry Al-Wassiti:</b> Passive targeting to the spleen by altering the physicochemical properties of lipid nanoparticles
14:20-14:30	Hangwen Li: A novel Core -shell structure LPP delivery platform for mRNA medicine
14:30-14:40	Christoph Rademacher: Targeted delivery to human Langerhans cells
14:40-15:00	Coffee Break
15:00-15:10	Bo Hansen: Preclinical evaluation of a modified mRNA for the treatment of OTC deficiency
15:10-15:20	<b>Caroline Woo:</b> Advancing the development of LNP-encapsulated mRNA therapeutics for pulmonary diseases
15:20-15:30	<b>Ajit Magadum:</b> mTORC1 Suppressor Modified mRNA Attenuated Cardiac Hypertrophy and Fibrosis in the Failing Heart
15:30-16:00	Poster Prize Awarding and Farewell